A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
de Braud F, Machiels JH, Boggiani D, Rottey SWH, Duca M, Laruelle M, Salvagni S, Damian S, Lapeire LDF, Tiseo M, Dermine A, Ould-Kaci M, Braunger J, Rascher J, Fischer D, Hoefler J, Mariani GL, Cresta S.
de Braud F, et al. Among authors: ould kaci m.
Cancers (Basel). 2020 May 31;12(6):1425. doi: 10.3390/cancers12061425.
Cancers (Basel). 2020.
PMID: 32486385
Free PMC article.